ALTSTATION.IO

Church & Dwight Co., Inc. (CHD) Stock Analysis

By Nova Skye | AltStation.io | Updated October 25, 2026

Price
$105.39
Change
-3.19%
Market Cap
$25.00B
Avg Volume
1.9M

Company Overview

Church and Dwight Co., Inc. is a consumer defensive company based in Ewing, New Jersey, that has been manufacturing household and personal care staples since 1846. The business operates across three distinct segments: Consumer Domestic, Consumer International, and Specialty Products. Their lineup spans essential everyday goods, including Arm and Hammer baking soda, OxiClean stain removers, Trojan condoms, and First Response test kits, along with livestock feed additives for agricultural producers. They sell these products directly to consumers through supermarkets, wholesale clubs, dollar stores, and e-commerce channels, as well as to industrial clients through commercial distributors.

Within the household and personal products space, Church and Dwight acts as a disciplined category leader by dominating targeted niches rather than fighting broad shelf-space wars. Their primary advantage lies in owning high-loyalty brands, including Waterpik in water flossers, Batiste in dry shampoo, and Arm and Hammer in cat litter and deodorizers. The main competitive threats come from lower-cost private-label store brands and legacy consumer packaged goods giants competing for the same retail floor space. By pairing premium personal care products with value-oriented lines like Xtra laundry detergent, the company maintains pricing flexibility when household budgets tighten.

The company is actively executing a growth strategy centered on expanding its higher-margin personal care footprint through targeted brand additions. Modern acquisitions like Hero acne treatments, TheraBreath oral care, and Touchland hand sanitizers now complement heritage health brands like Nair, Orajel, and Zicam. At the same time, the Specialty Products Division provides steady industrial diversification by selling prebiotics, probiotics, and sodium bicarbonate to dairy, beef, and poultry producers. This mix gives Church and Dwight a stable operating base where essential household demand consistently supports expansion into modern personal care categories.

Key Financials
Market Cap
$25.00B
Revenue
$6.23B
EBITDA
$1.35B
Gross Margin
45.6%
Profit Margin
12.0%
Revenue Growth
1.6%
Total Cash
$254.80M
Total Debt
$2.43B
Free Cash Flow
$939.26M


52-Week Price Performance Analysis

Price Statistics
P/E Ratio
33.78
Forward P/E
26.13
Beta
0.48
52-Week High
$108.93
52-Week Low
$81.33
EPS
$3.12
50-Day Avg
$98.56
200-Day Avg
$97.16
Price/Book
5.75
CHD 52-Week Stock Chart
Technical Analysis
CHD trades at $105.39, placing it 87% of the way from its $80.29 low to its $108.93 high. The stock is 3.43% below that high and 31.01% above the low. Price sits 5.33% above the 20-day moving average of $99.87, backed by 9.14% momentum over the last 20 trading days. Five-day momentum has slowed to 0.63%, suggesting the recent advance is losing some force. Near-term support is $94.11, while resistance is $108.86.


Recent News and Developments

Wall Street expects Q3 earnings growth on lower revenue

Church & Dwight will report third-quarter results on October 30. Analysts expect earnings of $0.90 per share, up 11.1% year over year, while projected revenue of $1.58 billion would be down 0.2%; the EPS consensus fell 0.24% over the past 30 days. Source: Zacks Equity Research

CHD hits a 52-week high, then gives back most of the gain

CHD climbed 3.68% on October 22, closing at $108.86 after reaching a 52-week high of $108.93. Shares reversed on October 23, falling 3.37% to $105.19. Source: StockAnalysis.com

Goldman puts CHD on its defensive-stock shortlist

Goldman Sachs included Church & Dwight in a 23-stock screen focused on health care and consumer-staples companies with low volatility and strong free-cash-flow characteristics. CHD had gained 24.1% year to date through the October 19 close. Source: Yahoo Finance



Market Sentiment and Analyst Recommendations

Bull Case
CHD has strong price momentum, rising 9.14% over the last 20 trading days and trading 5.33% above its 20-day moving average. The stock reached $108.93 on October 22, confirming demand near the top of its 52-week range. Wall Street expects third-quarter earnings of $0.90 per share, up 11.1% year over year. That earnings growth would be notable because projected revenue of $1.58 billion is down 0.2%, implying improved profitability if both estimates hold. Goldman Sachs included CHD in a 23-stock defensive screen focused on low volatility and strong free-cash-flow characteristics. The analyst recommendation is buy across 19 analysts, with the most bullish target at $115.00. Investors buying here are betting that earnings growth and defensive demand can outweigh the company’s modest 1.6% revenue growth.
Bear Case
CHD’s valuation is demanding at 33.78 times earnings while revenue growth is only 1.6%. The $105.39 share price is already above the $104.63 average analyst target. That leaves downside to the consensus target and limits the margin for disappointment. Projected third-quarter revenue of $1.58 billion is down 0.2%, so expected earnings growth is not being driven by top-line expansion. The EPS consensus also fell 0.24% over the past 30 days. CHD carries $2.43 billion in total debt against $254.80 million in cash, leaving debt more than nine times the cash balance. The October 23 decline of 3.37%, immediately after reaching a 52-week high, shows how quickly investors can sell near resistance.
What to Watch
The next major catalyst is the October 30 third-quarter report. Analysts expect earnings of $0.90 per share, up 11.1% year over year, and revenue of $1.58 billion, down 0.2%. A clear earnings beat would support the idea that CHD can expand profits despite weak revenue growth. A miss would be harder to excuse with the stock trading at a P/E of 33.78 and above the $104.63 average analyst target. On the chart, $108.86 is the immediate resistance level, followed closely by the $108.93 52-week high. A drop below the $99.87 moving average would weaken the current momentum, while $94.11 is the key near-term support level. Investors should also track whether the current 1.6% revenue growth improves, because a premium valuation needs more than cost-driven earnings gains.
Analyst Consensus
BUY

Based on 19 analyst opinions
Low Target
$78.00
Mean Target
$104.63
High Target
$115.00


Earnings and Financial Data

Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
5,550
Earnings & Dividends
Next Earnings
Oct 30, 2026
EPS (Trailing)
$3.12
Dividend Yield
113.0%
Payout Ratio
38.6%

Frequently Asked Questions

Is CHD a good stock to buy?
CHD has a buy recommendation from 19 analysts and trades 5.33% above its 20-day moving average. The takeaway is that sentiment and momentum are positive, but the 33.78 P/E makes the entry price demanding.
What is CHD’s price target?
The average analyst target is $104.63, with estimates ranging from $78.00 to $115.00. The takeaway is that the current $105.39 price already sits above the consensus target.
How close is CHD to its 52-week high?
CHD is 3.43% below its $108.93 52-week high and sits 87% of the way from its $80.29 low to that high. The takeaway is that CHD trades near the upper end of its annual range.
What are CHD’s support and resistance levels?
Near-term support is the 30-day low of $94.11, while resistance is the 30-day high of $108.86. The takeaway is that these are the key levels to watch for a breakdown or breakout.
How much debt does Church & Dwight have?
Church & Dwight has $2.43 billion in total debt and $254.80 million in total cash. The takeaway is that its debt balance substantially exceeds its available cash.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 25, 2026.